WebJan 25, 2024 · Ciltacabtagene autoleucel. The FDA extended the PDUFA date to February 28 2024 for the ciltacabtagene autoleucel (cilta-cel) biologics license application (BLA). The original target action date was November 29 2024. The FDA extended the PDUFA date to allow sufficient time to review information recently submitted by the company pertaining … WebOct 1, 2024 · The FDA was set to decide on approval by August, too, but extended its review to go over two-year results that BioMarin submitted from a Phase 3 trial. Those results have shown that treatment with vosoritide led to greater gains in height than a placebo in year two, and position BioMarin well for a positive decision.
FDA Calendar and Recent FDA News - Benzinga
WebApr 8, 2024 · The second quarter of 2024 is shaping up to a formative one for the pharmacotherapeutic fields of chronic disease; among the dozens of US Food and Drug Administration (FDA) PDUFA decision dates on the docket through June are a handful of first-in-class treatments, novel agents, and familiar drugs with refined indication capabilities. WebComirnaty (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine that is indicated for active immunization to prevent COVID-19 in individuals 12 years of age and older. It is approved for use as a 2-dose primary series for the prevention of COVID-19 in individuals 12 years of age and older. Comirnaty and Pfizer-BioNTech COVID-19 … smpewn
Biotech Stock Weekly Watch List • BioPharmCatalyst
WebApr 8, 2024 · The second quarter of 2024 is shaping up to a formative one for the pharmacotherapeutic fields of chronic disease; among the dozens of US Food and Drug … WebOct 7, 2024 · FDA Calendar. October 7, 2024. A + A -. These can be significant catalyst events for biotech and pharma stocks when the decisions are announced. In addition to the actual FDA decision biotech … WebOct 1, 2024 · The FDA accepted the avacopan NDA for review on Sept. 17, 2024, and set an original PDUFA goal date of July 7. An FDA panel that reviewed the NDA in early May issued a split verdict. rjah attend anywhere